At 150-300 mg UMP, oral, daily:

• Onset over days to weeks, not minutes. Most users feel nothing acutely.
• By week 2-4, a subset report subtle mood lift, slightly easier task initiation, mild "clean motivation."
• ~30-40% of users report no detectable effect even after 8-12 weeks.

At 500 mg UMP, oral, daily, paired with DHA + choline:

• The Wurtman-triad protocol. Subjective effects more consistent — most users describe mild-but-real cognitive baseline improvement, mood smoothing, sometimes vivid dreams.
• Effect typically clearer when stacked than mono-uridine.

At 25-50 mg TAU, sublingual:

• Stronger per-mg subjective effect (BBB-bypass + lipophilic absorption). Some users describe a mild dopaminergic feel — "clean motivation," easier initiation. Distinct from caffeine, distinct from alpha-GPC.
• Onset 30-60 min sublingual; duration 4-6 hr.

Variability:

• High inter-individual variability. Substrate supplements feel-effect depends heavily on baseline diet (DHA-rich vs DHA-poor), choline status, and age (older brains tend to feel substrate support more than young brains do).
• Young healthy users on a balanced diet often report subtle or no effect — they're not substrate-limited.

• Receptor tolerance: none. Uridine is a substrate, not an agonist. No documented downregulation pattern.
• Subjective effect tolerance: some users report fading subjective effect at 6-12 weeks. Likely reflects substrate saturation rather than receptor adaptation — once the membrane-phosphatide pool is replete, additional uridine has diminishing returns.
• Cycling: not required. Some community protocols suggest 8 weeks on / 2 weeks off, but no mechanistic basis. Continuous dosing is fine for most users.

Synergistic with

• Fish oil (DHA / EPA): ✅ The canonical Wurtman pairing. DHA is the fatty-acid tail; uridine is the cytidine donor. Inseparable for the synaptogenesis use case. DHA 1-2 g/day + UMP 250-500 mg/day is the standard combo.
• Citicoline (CDP-choline): ✅ Citicoline already supplies cytidine + choline + phosphate (it IS reassembled CDP-choline). Adding UMP further raises plasma uridine. Modest redundancy, not antagonism. Pick one path: citicoline alone (combined cholinergic + cytidine package) OR UMP + separate choline (modular).
• Alpha-GPC: ✅ Alpha-GPC supplies the choline arm; UMP supplies the cytidine arm; together with DHA → full Kennedy substrate triad. Stack-friendly when alpha-GPC is the chronic choline source.
• Racetams (piracetam, aniracetam, oxiracetam, phenylpiracetam): ✅ Racetams modulate AMPA + cholinergic transmission and reportedly consume choline faster (the "racetam headache"). UMP + choline + DHA provides membrane-phosphatide substrate that supports racetam tolerance.
• Magnesium L-threonate: ✅ Threonate's NMDA / synaptic-plasticity profile is mechanistically complementary. No conflict.
• Phosphatidylserine (PS): ✅ Both feed membrane-phospholipid pool from different angles (intact phosphatide vs precursor). Common combo in cognitive-decline protocols.
• L-tyrosine: ✅ Catecholamine substrate vs membrane-phosphatide substrate — orthogonal. Stack-safe.

Avoid stacking with

• 5-Fluorouracil (5-FU) / capecitabine chemotherapy: ❌ Uridine antagonizes 5-FU. Vistogard (uridine triacetate) is FDA-approved as an emergency 5-FU overdose antidote specifically because uridine outcompetes 5-FU at thymidylate synthase. Outside the rescue context, supplementing uridine during scheduled chemo blunts the intended antineoplastic effect. Coordinate with oncology — do not self-stack.

Neutral / safe co-administration

• All standard nootropics (caffeine, theanine, modafinil, semax, ALCAR, creatine, NAC).
• All standard supplements (D3+K2, magnesium, B-complex, vitamin C).
• All adaptogens (ashwagandha, rhodiola).
• All BPC-157-class peptides (different therapeutic axis).

• Allopurinol / xanthine oxidase inhibitors: Theoretical — pyrimidine catabolism intersects with purine handling. Clinically not a documented problem, but gout patients should mention uridine supplementation to their clinician.
• 5-FU / capecitabine: Major antagonism (see above). FDA-approved as 5-FU antidote.
• Anticoagulants, antiplatelets, statins, antihypertensives, hormonal contraceptives: No documented interaction.
• CYP enzymes: Uridine does not meaningfully induce or inhibit CYP. Pharmacokinetic interactions essentially nil.
• L-DOPA / dopamine agonists (Parkinson's): No documented interaction; theoretical synergy via D2 sensitization is preclinical-only.

Minimal direct PGx data for uridine specifically. Relevant indirect variants:

• DPYD (dihydropyrimidine dehydrogenase): rate-limiting enzyme in pyrimidine catabolism. DPYD-deficient patients are at risk for severe 5-FU toxicity; uridine handling is also affected, though clinically meaningful only in chemo context.
• SLC28A1 / SLC29A1 (concentrative / equilibrative nucleoside transporters): variants may modulate BBB uridine transport. Limited clinical data.
• UCK2 (uridine-cytidine kinase 2): polymorphisms could theoretically modulate brain uridine → UMP conversion efficiency. No clinical data.
• APOE ε4: general modulator of cognitive-decline-prevention response. ε4 carriers may benefit more from membrane-phosphatide substrate support (LipiDiDiet did stratify by APOE; signal patterns generally consistent across genotypes but underpowered).

Action for users in this archetype: When 23andMe results land (~June 5-15, 2026), check APOE ε4. If ε4+, uridine moves slightly toward STRONG-CANDIDATE for chronic membrane-substrate support alongside citicoline + DHA.

Recommendation for users in this archetype: Nootropics Depot UMP 300 mg × 60 caps via direct order (~$20, 60 doses). One cap daily AM with fish oil + citicoline. Total cost: ~$10/month steady-state. Negligible relative to overall stack budget.

Total cost estimate (the user): ~$5-15/month at typical doses. Cheap.

Baseline (optional; not strictly required for OTC supplementation)

• Subjective cognition + mood scale — daily log for 4 weeks, then weekly (PHQ-9, custom 1-10 scales)
• Sleep quality — Oura/ring data if tracking
• BDNF (serum) — optional; if running a comprehensive biomarker panel
• Lipid panel + B12 + folate + homocysteine — general baseline; uridine works through methylation-adjacent pathways

During use

• Subjective tracking: daily 1-10 mood/cognition scale for first 4 weeks → weekly
• No specific safety lab required — uridine has no documented organ-toxicity profile at supplement doses

Discontinuation criteria

• No subjective benefit by 12 weeks at 250-500 mg/day → discontinue
• Persistent GI / headache / mood destabilization → discontinue and reassess
• Active chemo with 5-FU class → pause immediately